MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $63.56 (38.68% upside)

Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX)
Show:
DateFirmActionRatingPrice TargetActions
5/25/2016Jefferies GroupReiterated RatingBuy$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Piper JaffrayReiterated RatingOverweight$96.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Robert W. BairdReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016BMO Capital MarketsReiterated RatingOutperform$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016Cowen and CompanyReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Leerink SwannReiterated RatingBuy$71.00 -> $76.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Deutsche BankBoost Price TargetBuy$35.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015BarclaysInitiated CoverageOverweight$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2015RBC CapitalInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014MKM PartnersReiterated RatingBuy$20.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/26/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha